Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
Study Meets Primary and Key Secondary Endpoints with High Statistical Significance
Statistically Significant Reduction of 62% and 70%
Data Supports Previously Observed Favorable Safety Profile of IMU-838 in Relapsing-Remitting Multiple Sclerosis Patient Population -
- Company Also Reports Second Quarter 2020 Financial Results With $48.6 Million in Cash and Cash Equivalents -
finance.yahoo.c...-190000055.html?guce_refer...
Study Meets Primary and Key Secondary Endpoints with High Statistical Significance
Statistically Significant Reduction of 62% and 70%
Data Supports Previously Observed Favorable Safety Profile of IMU-838 in Relapsing-Remitting Multiple Sclerosis Patient Population -
- Company Also Reports Second Quarter 2020 Financial Results With $48.6 Million in Cash and Cash Equivalents -
finance.yahoo.c...-190000055.html?guce_refer...